Why is it that decades of attack has gone nowhere? Think about it. they were beating up on this horse back in the sixties. It is not addictive yet it does not go away. The truth is spelled out here. Laetrile is effective in suppressing the actual spread of cancer and this was properly confirmed forty five years ago.
In the early 1970s, America’s war on cancer was in full force, and Sloan Kettering was regarded as one of the world’s leading cancer research centers.
But Sloan Kettering’s Board of Directors swept positive findings about Laetrile under the rug when it became unprofitable and publicly unpopular for them to support it.
Their Laetrile research was done under their own roof by one of the world’s most respected cancer researchers of the day—Dr. Kanematsu Sugiura. One person—and only one—has come forward with the truth about what turned out to be one of the most reprehensible cover-ups in the history of cancer research.
In 1974, young science writer Ralph Moss had just netted his first big-time job in Sloan Kettering’s public relations department, but he soon found himself smack dab in the middle of the Laetrile fiasco.
In July 1977, Moss was no longer willing to lie on behalf of his employer, so he exposed the truth about Sloan Kettering’s conduct at a highly publicized press conference. The next business day he was fired and swiftly escorted to the door by armed guards.
This story is personally recounted in a new documentary Second Opinion: Laetrile at Sloan Kettering, in which Moss reveals the full extent of the Laetrile cover-up, in its entirety, as an insider. He’s also written a book about it, called Doctored Results.
Eric Merola is an award winning documentarian whose prior work includes Burzynski: The Movie and Burzynski—Cancer is Serious Business, Part II. The experience was life changing for Ralph Moss, who has since devoted his career to independently evaluating the claims of conventional and nonconventional cancer treatments.
The fact that mainstream media has embraced this documentary with positive reviews is rather astonishing, and perhaps a sign of changing times.
“Though a documentary, it’s dramatic enough to be reminiscent of ‘The Insider,’ the whistleblowing thriller about Big Tobacco.”
—Graham Fuller, New York Daily News, August 28, 2014
- August 2014: In a new German study, amygdalin dose-dependently reduced growth and proliferation of bladder cancer
- May 2013: Amygdalin inhibits renal fibrosis in chronic kidney disease; researchers conclude it is a “potent antifibrotic agent that may have therapeutic potential for patients with fibrotic kidney diseases”
- February 2013: Amygdalin induces apoptosis in human cervical cancer cells; authors conclude it may offer a new therapeutic option for cervical cancer patients
- February 2003: Amygdalin from Prunus persica seeds (peach pits) shows anti-tumor effects comparable to epigallocatechin gallate in green tea